Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8338470 | HOSPIRA | Dexmedetomidine premix formulation |
Jan, 2032
(8 years from now) | |
US8455527 | HOSPIRA | Methods of treatment using a dexmedetomidine premix formulation |
Jan, 2032
(8 years from now) | |
US8648106 | HOSPIRA | Dexmedetomidine premix formulation |
Jan, 2032
(8 years from now) | |
US9616049 | HOSPIRA | Dexmedetomidine premix formulation |
Jan, 2032
(8 years from now) | |
US8242158 | HOSPIRA | Dexmedetomidine premix formulation |
Jan, 2032
(8 years from now) | |
US10016396 | HOSPIRA | Dexmedetomidine premix formulation |
Jan, 2032
(8 years from now) | |
US9320712 | HOSPIRA | Dexmedetomidine premix formulation |
Jan, 2032
(8 years from now) | |
US9616049 (Pediatric) | HOSPIRA | Dexmedetomidine premix formulation |
Jul, 2032
(8 years from now) | |
US8648106 (Pediatric) | HOSPIRA | Dexmedetomidine premix formulation |
Jul, 2032
(8 years from now) | |
US8242158 (Pediatric) | HOSPIRA | Dexmedetomidine premix formulation |
Jul, 2032
(8 years from now) | |
US8455527 (Pediatric) | HOSPIRA | Methods of treatment using a dexmedetomidine premix formulation |
Jul, 2032
(8 years from now) | |
US9320712 (Pediatric) | HOSPIRA | Dexmedetomidine premix formulation |
Jul, 2032
(8 years from now) | |
US8338470 (Pediatric) | HOSPIRA | Dexmedetomidine premix formulation |
Jul, 2032
(8 years from now) |
Precedex is owned by Hospira.
Precedex contains Dexmedetomidine Hydrochloride.
Precedex has a total of 13 drug patents out of which 0 drug patents have expired.
Precedex was authorised for market use on 17 December, 1999.
Precedex is available in injectable;injection dosage forms.
Precedex can be used as use for sedation.
The generics of Precedex are possible to be released after 04 July, 2032.
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Patient Population (NPP) | Dec 16, 2025 |
Drugs and Companies using DEXMEDETOMIDINE HYDROCHLORIDE ingredient
Market Authorisation Date: 17 December, 1999
Treatment: Use for sedation
Dosage: INJECTABLE;INJECTION
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic